Dan Roden
Faculty Member
Last active: 3/24/2020

Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.

Roden DM, Van Driest SL, Wells QS, Mosley JD, Denny JC, Peterson JF
Circ Res. 2018 122 (9): 1176-1190

PMID: 29700066 · PMCID: PMC5926807 · DOI:10.1161/CIRCRESAHA.117.310965

This review will provide an overview of the principles of pharmacogenomics from basic discovery to implementation, encompassing application of tools of contemporary genome science to the field (including areas of apparent divergence from disease-based genomics), a summary of lessons learned from the extensively studied drugs clopidogrel and warfarin, the current status of implementing pharmacogenetic testing in practice, the role of genomics and related tools in the drug development process, and a summary of future opportunities and challenges.

© 2018 American Heart Association, Inc.

MeSH Terms (20)

Biological Variation, Individual Biotransformation Cardiovascular Agents Drug-Related Side Effects and Adverse Reactions Drug Development Forecasting Genetic Association Studies Genetic Predisposition to Disease Genetic Testing Genetic Variation Genomics Genomics Genotyping Techniques Human Genome Project Humans Pharmacogenetics Precision Medicine Randomized Controlled Trials as Topic Risk Assessment Sample Size

Connections (1)

This publication is referenced by other Labnodes entities: